Theralase Technologies Inc. (TLTFF) Q2 2024 Earnings Call Transcript
Theralase Technologies Inc. (OTCQX:TLTFF) Q2 2024 Earnings Conference Call August 21, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Officer Roger Dumoulin-White - President and Chief Executive Officer Conference Call Participants Matthew Perraton Good morning everyone. My name is Matthew Perraton and I will be hosting Theralase Technologies Inc's Quarterly Investor Conference Call today.
Theralase Technologies reports ability to activate Rutherrin with diabetes drug
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin has been shown preclinically to be activated by the common diabetes drug Metformin without the use of light or radiation. The company highlighted that because both drugs are proven to cross the blood-brain barrier and tumor-specific blood barriers, this discovery could potentially allow for the precise targeting of cancer cells by Metformin-activated Rutherrin anywhere in the body, including the brain.
Theralase nears completion of bladder cancer study with promising results - ICYMI
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) recently announced significant progress in the company's bladder cancer clinical study, now involving 72 patients, with expectations to reach 85 by year-end. CEO Roger Dumoulin-White spoke with Proactive about the significance of these results for both the FDA and the broader medical community in preventing disease progression, as well as the urgency of nearing completion, especially since a competitor received FDA approval with just 77 patients earlier this year.
Theralase Technologies bladder cancer study achieves key milestones
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF), a pioneer in the research and development of light and/or radiation-activated small molecules targeting cancers, bacteria and viruses, has reported its financial results for the second quarter and provided an update on its research activities. The company said that to date, it has enrolled and treated 72 patients in Study II, which is evaluating its patented drug Rudivar and proprietary device in patients with Bacille Calmette–Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in-situ (CIS).
Theralase Technologies reports Rutherrin boosts effectiveness of non-cancer drugs in cancer therapy
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead drug formulation Rutherrin was able to repurpose non-cancer drugs for cancer therapy in preclinical research. The company, which is developing light and/or radiation-activated small molecule compounds, their associated drug formulations and the light systems that activate them, highlighted there is growing interest in repurposing drugs that have established safety, pharmacokinetics and efficacy and repurposing them for cancer to reduce the cost and time taken to bring therapies to market.
Theralese Technologies reports complete response in preclinical lung cancer model
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF). (TSXV OTCQB), a clinical-stage pharmaceutical company specializing in light and radiation-activated therapies, has announced that its lead drug formulation, Rutherrin, has shown promising results in a Non-Small Cell Lung Cancer (NSCLC) animal model.
Theralase Technologies reports lead drug Rutherrin enhances immunotherapy
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that new preclinical research has shown its lead drug formulation Rutherrin has demonstrated the ability to increase the efficiency of immunotherapy. Immunotherapy aims to harness an individual's immune system to detect and destroy cancer cells.
Theralase reports preclinical research shows Rutherrin enhances chemotherapy efficacy
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that preclinical research results for its lead drug formulation, Rutherrin, has demonstrated its effectiveness in enhancing chemotherapy efficacy. The drug formulation also showed success in reducing multidrug resistance (MDR) in cancer treatment, the company reported.
Theralase Technologies hails new combination treatment for NMI bladder cancer in pre-clinical tests
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) said that a combination of its lead compound with a widely used treatment to make a much more effective therapy for non-muscle invasive bladder cancer (NMIBC). In pre-clinical research, the company's lead compound, Ruvidar, when combined with the bacillus Calmette-Guérin (BCG) vaccine, has formed a new compound named RuBCG, that exhibits new synergistic characteristics.
Theralase Technologies Inc. (TLTFF) Q1 2024 Earnings Call Transcript
Theralase Technologies Inc. (OTCQX:TLTFF) Q1 2024 Results Conference Call June 6, 2024 11:00 AM ET Company Participants Matthew Perraton - Chairman of the Board Kristina Hachey - Chief Financial Officer Roger Dumoulin-White - President and Chief Executive Officer Matthew Perraton Today's call will focus on a presentation and discussion of the Company's First Quarter 2024 Interim Financial Statements and an update on our Phase II bladder cancer clinical study followed by a question-and-answer period for each. The agenda for the call today will be a presentation by Kristina Hachey, Chief Financial Officer of Theralase, on the first quarter interim financial statements.
Theralase eyes Phase 1a trial for lung cancer therapy after preclinical success
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that its lead compound Rudivar combined with transferrin to form the compound Rutherrin has been shown to be effective in the destruction of Non-Small Cell Lung Cancer in a preclinical study. The clinical-stage pharmaceutical company developing light and/or radiation-activated small molecule compounds said the results came from its recent experiments using a Lewis Lung Cancer orthotopic model.
Theralase Technology unveils new research showing Rudivar's effectiveness against multiple viruses
Theralase Technologies Inc (TSX-V:TLT, OTCQB:TLTFF) announced that new research has shown that its lead asset Rudivar has proven effective in the inactivation of various viruses. The company, which is developing light and/or radiation-activated small molecules, added that when the human coronaviruses was treated with Rudivar, the spike protein remained intact.
